Poseida Therapeutics poseida.com


Public list: Synthetic Biology (153) Pharma Startups (6570) Cancer Therapeutics (1180)

Poseida Therapeutics is a clinical-stage biotechnology company translating gene engineering technologies into lifesaving treatments for patients with high unmet medical need. The company is developing a wholly-owned pipeline of autologous and allogeneic CAR-T product candidates, initially focused on the treatment of hematological malignancies and solid tumors, as well as gene therapies for orphan genetic diseases.

Poseida Therapeutics is a clinical-stage biotechnology company translating gene engineering technologies into lifesaving treatments for patients with high unmet medical need. The company is developing a wholly-owned pipeline of autologous and allogen...Show all

Company (Alive / Active)

Phone: (858)-779-3100

Fax:

9390 Towne Centre Drive
Suite 200
San Diego, 92121
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Poseida Therapeutics $213.7M Apr 22, 2019

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Poseida Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Longitude CapitalVenture CapitalMenlo Park, California, United StatesSeries C, Series B
Aisling CapitalPrivate EquityNew York, New York, United StatesSeries C
JLabsIncubator/AcceleratorSan Diego, California, United StatesIncubator/Accelerator
Boxer CapitalCorporate VentureWindermere, Florida, United StatesSeries C
Malin CorporationHolding CompanyDun Laoghaire, IrelandSeries C, Series B, Corporate Minority, Series A
See all 13 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Hyperactive piggybac transposases Feb 22, 2013 Jan 17, 2017 Patent
Hyperactive piggybac transposases Dec 20, 2017 Application
Hyperactive piggybac transposases Jul 28, 2016 Application
Methods and compositions for in vivo non-covalent linking Jun 17, 2015 Application
A method for directing proteins to specific loci in the genome and uses thereof Jun 17, 2015 Application